Gallus BioPharmaceutical Aquires CMO Laureate Biopharmaceutical Services

Article

he CMO Gallus BioPharmaceutical has acquired the biologics CMO Laureate Biopharmaceutical Services.

Gallus BioPharmaceuticals, a St. Louis-based CMO has acquired Laureate Biopharmaceutical Services, a biologics CMO located in Princeton, New Jersey. This acquisition doubles Gallus’ process development and clinical drug-substance-manufacturing capacity and adds full protein characterization, testing, and clinical fill-finish capability. With the acquisition, Gallus has two centers of excellence. The Princeton site is a Center of Excellence for process development and manufacture of clinical-stage products, including fill-finish, and the St. Louis site is a Center of Excellence for process development and clinical and commercial manufacture of biopharmaceutical products.

Gallus has clinical and commercial suites at both sites, with 50-L to 2000-L GMP single-use platforms from Xcellerex and HyClone in addition to 50-L to 2000L fixed and flexible stainless-steel bioreactors and associated downstream purification for drug substances.

Source: Gallus BioPharmaceuticals

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.